RECRUITINGOBSERVATIONAL
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
About This Trial
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age between 50 and 99
Who Should NOT Join This Trial:
- Presence of clinical PD at the time of study inclusion
- Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
- other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
- in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age between 50 and 99
Exclusion Criteria:
* Presence of clinical PD at the time of study inclusion
* Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis)
* other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment
* in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
Treatments Being Tested
OTHER
No intervention
No intervention
Locations (1)
Department for Neurology, University of Kiel
Kiel, Germany